Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia

被引:42
|
作者
Barak, Segev [1 ]
Arad, Michal [1 ]
De Levie, Amaya [1 ]
Black, Mark D. [2 ]
Griebel, Guy [3 ]
Weiner, Ina [1 ]
机构
[1] Tel Aviv Univ, Dept Psychol, IL-69978 Tel Aviv, Israel
[2] Sanofi Aventis, CNS Dept, Bridgewater, NJ USA
[3] Sanofi Aventis, CNS Dept, Bagneux, France
基金
以色列科学基金会;
关键词
alpha 7 nicotinic receptors; cognition; latent inhibition; schizophrenia; positive symptoms; SSR180711; NITRIC-OXIDE SYNTHASE; ACETYLCHOLINE-RECEPTOR AGONISTS; NUCLEUS-ACCUMBENS DOPAMINE; ANIMAL-MODELS; PREPULSE INHIBITION; ALLOSTERIC MODULATOR; CONSTRUCT-VALIDITY; NEGATIVE SYMPTOMS; ACOUSTIC STARTLE; GATING DEFICITS;
D O I
10.1038/npp.2008.232
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Schizophrenia symptoms can be segregated into positive, negative and cognitive, which exhibit differential sensitivity to drug treatments. Accumulating evidence points to efficacy of alpha 7 nicotinic receptor (nAChR) agonists for cognitive deficits in schizophrenia but their activity against positive symptoms is thought to be minimal. The present study examined potential pro-cognitive and antipsychotic activity of the novel selective a7 nAChR partial agonist SSR180711 using the latent inhibition (LI) model. LI is the reduced efficacy of a previously non-reinforced stimulus to gain behavioral control when paired with reinforcement, compared with a novel stimulus. Here, no-drug controls displayed LI if non-reinforced pre-exposure to a tone was followed by weak but not strong conditioning (2 vs 5 tone-shock pairings). MK801 (0.05 mg/kg, i.p.)-treated rats as well as rats neonatally treated with nitric oxide synthase inhibitor L-NoArg (10 mg/kg, s.c.) on postnatal days 4-5, persisted in displaying LI with strong conditioning, whereas amphetamine (1 mg/kg) -treated rats failed to show LI with weak conditioning. SSR180711 (0.3, 1, 3 mg/kg, i.p.) was able to alleviate abnormally persistent LI produced by acute MK801 and neonatal L-NoArg; these models are believed to model cognitive aspects of schizophrenia and activity here was consistent with previous findings with alpha 7-nAChR agonists. In addition, unexpectedly, SSR180711 (1, 3 mg/kg, i.p.) potentiated LI with strong conditioning in no-drug controls and reversed amphetamine-induced LI disruption, two effects considered predictive of activity against positive symptoms of schizophrenia. These findings suggest that SSR180711 may be beneficial not only for the treatment of cognitive symptoms in schizophrenia, as reported multiple times previously, but also positive symptoms. Neuropsychopharmacology (2009) 34, 1753-1763; doi:10.1038/npp.2008.232; published online 21 January 2009
引用
收藏
页码:1753 / 1763
页数:11
相关论文
共 19 条
  • [1] Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
    Segev Barak
    Michal Arad
    Amaya De Levie
    Mark D Black
    Guy Griebel
    Ina Weiner
    Neuropsychopharmacology, 2009, 34 : 1753 - 1763
  • [2] SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia
    Philippe Pichat
    Olivier E Bergis
    Jean-Paul Terranova
    Alexandre Urani
    Christine Duarte
    Vincent Santucci
    Christiane Gueudet
    Carole Voltz
    Régis Steinberg
    Jeanne Stemmelin
    Florence Oury-Donat
    Patrick Avenet
    Guy Griebel
    Bernard Scatton
    Neuropsychopharmacology, 2007, 32 : 17 - 34
  • [3] SSR180711, a novel selective α7 nicotinic receptor partial agonist:: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia
    Pichat, Philippe
    Bergis, Olivier E.
    Terranova, Jean-Paul
    Urani, Alexandre
    Duarte, Christine
    Santucci, Vincent
    Gueudet, Christiane
    Voltz, Carole
    Steinberg, Regis
    Stemmelin, Jeanne
    Oury-Donat, Florence
    Avenet, Patrick
    Griebel, Guy
    Scatton, Bernard
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 17 - 34
  • [4] SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile
    Bruno Biton
    Olivier E Bergis
    Frédéric Galli
    Alain Nedelec
    Alistair W Lochead
    Samir Jegham
    Danielle Godet
    Christophe Lanneau
    Raphaël Santamaria
    Françoise Chesney
    Jacques Léonardon
    Patrick Granger
    Marc W Debono
    Georg A Bohme
    Frédéric Sgard
    François Besnard
    David Graham
    Annick Coste
    André Oblin
    Olivier Curet
    Xavier Vigé
    Corinne Voltz
    Liliane Rouquier
    Josiane Souilhac
    Vincent Santucci
    Christiane Gueudet
    Dominique Françon
    Régis Steinberg
    Guy Griebel
    Florence Oury-Donat
    Pascal George
    Patrick Avenet
    Bernard Scatton
    Neuropsychopharmacology, 2007, 32 : 1 - 16
  • [5] SSR180711, a novel selective α7 nicotinic receptor partial agonist:: (I) binding and functional profile
    Biton, Bruno
    Bergis, Olivier E.
    Galli, Frederic
    Nedelec, Alain
    Lochead, Alistair W.
    Jegham, Samir
    Godet, Danielle
    Lanneau, Christophe
    Santamaria, Raphael
    Chesney, Francois
    Leonardon, Jacques
    Granger, Patrick
    Debono, Marc W.
    Bohme, Georg A.
    Sgard, Frederic
    Besnard, Francois
    Graham, David
    Coste, Annick
    Oblin, Andre
    Curet, Olivier
    Vige, Xavier
    Voltz, Corinne
    Rouquier, Liliane
    Souilhac, Josiane
    Santucci, Vincent
    Gueudet, Christiane
    Francon, Dominique
    Steinberg, Regis
    Griebel, Guy
    Oury-Donat, Florence
    George, Pascal
    Avenet, Patrick
    Scatton, Bernard
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 1 - 16
  • [6] Interaction of SSR180711, a selective α7 nicotinic receptor partial agonist, with PNU120596:: Evidence for several α7 nicotinic receptor desensitized states
    Biton, Bruno
    Khessibi, Nejla
    Le-Metayer, Danielle
    Lanneau, Christophe
    Oury-Donat, Florence
    Avenet, Patrick
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (08) : SMA15 - SMA15
  • [7] LOCALIZED INFUSIONS OF THE PARTIAL ALPHA 7 NICOTINIC RECEPTOR AGONIST SSR180711 EVOKE RAPID AND TRANSIENT INCREASES IN PREFRONTAL GLUTAMATE RELEASE
    Bortz, D. M.
    Mikkelsen, J. D.
    Bruno, J. P.
    NEUROSCIENCE, 2013, 255 : 55 - 67
  • [8] Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711
    Hashimoto, Kenji
    Ishima, Tamaki
    Fujita, Yuko
    Matsuo, Masaaki
    Kobashi, Tatsuhiro
    Takahagi, Makoto
    Tsukada, Hideo
    Iyo, Masaomi
    BIOLOGICAL PSYCHIATRY, 2008, 63 (01) : 92 - 97
  • [9] SSR180711, an α7 nicotinic receptor partial agonist, reverses memory deficits induced by β25-35 amyloid peptide icv administration in mice
    Urani, A.
    Bergis, O. E.
    Griebel, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S489 - S489
  • [10] In vitro pharmacological characterization and pro-cognitive effects of the selective alpha-7 nicotinic agonist WYE-103914
    Dunlop, J.
    Comery, T. A.
    Lock, T.
    Kramer, A.
    Kowal, D.
    Yeola, S.
    Jow, F.
    Aschmies, S.
    Lin, Q.
    Beyer, C. E.
    Brennan, J.
    Kelley, C.
    Roncarati, R.
    Scali, C.
    Haydar, S.
    Ghiron, C.
    Marquis, K. L.
    Harrison, B.
    Robichaud, A.
    Terstappen, G. C.
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) : 911 - 911